IQVIA与SocialMED达成独家战略合作 智能营销全方位升维

10月31日，IQVIA宣布与醴泽资本旗下的SocialMED（下称“智云”）达成独家战略合作，共建基于人工智能的远程数字化营销服务解决方案，成立中国数字化销售代表运营中心，联动线上线下渠道，将数据和算法真正转化为商业创新和实践，共同推动数字化精准营销升维，释放数字智慧医疗价值。

汪洋专程调研省政协委员微泰医疗总经理郑攀博士牵头的海创园政协委员会客厅

10月25日，中共中央政治局常委、全国政协主席汪洋在浙江调研政协工作，全国政协副主席兼秘书长夏宝龙参加调研，并在省委书记车俊、省长袁家军、省政协主席葛慧君、杭州市委书记周江勇和市政协主席潘家玮等领导陪同下，专程到杭州未来科技城考察调研省政协委员郑攀牵头开展的政协委员会客厅工作，听取了郑攀委员的汇报。

Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China

SAN DIEGO, Calif., October 22, 2019 – Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that it has entered into a multi-product collaboration with Brii Biosciences to develop and commercialize Qpex’s portfolio in China of potentially best-in-class therapies to treat a range of multi-drug resistant gram-negative infections.

Qpex Biopharma to Present its Anti-infective Portfolio at IDWeek 2019

SAN DIEGO, September 25, 2019 –Qpex Biopharma today announced scientific presentations on its investigational anti-infectives at the IDWeek 2019 Conference to be held October 2-6 in Washington, DC.

Chipscreen sets pace for biotech IPOs in Shanghai

Shanghai IPO values Chipscreen at $1.2B, opening the door for biopharma listings on the STAR market

Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting

SAN DIEGO, June 13, 2019 /PRNewswire/ -- Qpex Biopharma today announced that preclinical data on its investigational beta-lactamase inhibitor QPX7728 will be featured in several presentations at the 2019 ASM Microbe Meeting to be held June 20-24 in San Francisco, CA.